These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 18642204)
1. [In vitro studies on the mechanism of action of VEGF and its inhibitors]. Deissler HL; Lang GE Klin Monbl Augenheilkd; 2008 Jul; 225(7):623-8. PubMed ID: 18642204 [TBL] [Abstract][Full Text] [Related]
2. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells. Deissler H; Deissler H; Lang S; Lang GE Br J Ophthalmol; 2008 Jun; 92(6):839-43. PubMed ID: 18511543 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells. Deissler HL; Deissler H; Lang GE Br J Ophthalmol; 2011 Aug; 95(8):1151-6. PubMed ID: 21273213 [TBL] [Abstract][Full Text] [Related]
4. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells. Deissler HL; Lang GK; Lang GE Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334 [TBL] [Abstract][Full Text] [Related]
6. Altered expression of genes related to blood-retina barrier disruption in streptozotocin-induced diabetes. Klaassen I; Hughes JM; Vogels IM; Schalkwijk CG; Van Noorden CJ; Schlingemann RO Exp Eye Res; 2009 Jun; 89(1):4-15. PubMed ID: 19284967 [TBL] [Abstract][Full Text] [Related]
7. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Harhaj NS; Felinski EA; Wolpert EB; Sundstrom JM; Gardner TW; Antonetti DA Invest Ophthalmol Vis Sci; 2006 Nov; 47(11):5106-15. PubMed ID: 17065532 [TBL] [Abstract][Full Text] [Related]
8. [Effect of VEGF165 and the VEGF aptamer pegaptanib (Macugen) on the protein composition of tight junctions in microvascular endothelial cells of the retina]. Deissler HL; Lang GE Klin Monbl Augenheilkd; 2008 Oct; 225(10):863-7. PubMed ID: 18951306 [TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Caldwell RB; Bartoli M; Behzadian MA; El-Remessy AE; Al-Shabrawey M; Platt DH; Caldwell RW Diabetes Metab Res Rev; 2003; 19(6):442-55. PubMed ID: 14648803 [TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases. Singh H; Milner CS; Aguilar Hernandez MM; Patel N; Brindle NP Cell Signal; 2009 Aug; 21(8):1346-50. PubMed ID: 19376222 [TBL] [Abstract][Full Text] [Related]
11. Decursin inhibits VEGF-mediated inner blood-retinal barrier breakdown by suppression of VEGFR-2 activation. Kim JH; Kim JH; Lee YM; Ahn EM; Kim KW; Yu YS J Cereb Blood Flow Metab; 2009 Sep; 29(9):1559-67. PubMed ID: 19536074 [TBL] [Abstract][Full Text] [Related]
12. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Lowe J; Araujo J; Yang J; Reich M; Oldendorp A; Shiu V; Quarmby V; Lowman H; Lien S; Gaudreault J; Maia M Exp Eye Res; 2007 Oct; 85(4):425-30. PubMed ID: 17714704 [TBL] [Abstract][Full Text] [Related]
14. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666 [TBL] [Abstract][Full Text] [Related]
15. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Yang J; Wang X; Fuh G; Yu L; Wakshull E; Khosraviani M; Day ES; Demeule B; Liu J; Shire SJ; Ferrara N; Yadav S Mol Pharm; 2014 Oct; 11(10):3421-30. PubMed ID: 25162961 [TBL] [Abstract][Full Text] [Related]